z-logo
Premium
The phosphotyrosine phosphatase inhibitor‐phenylarsine oxide restores defective phosphoinositide hydrolysis response in anergic C3H‐ gld/gld lymphocytes
Author(s) -
LING WEIJUN,
TIBBETTS DIANE J,
CRAIN RICHARD C,
LYNES MICHAEL A
Publication year - 1996
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1038/icb.1996.42
Subject(s) - phenylarsine oxide , biology , population , microbiology and biotechnology , cd8 , receptor , immunology , endocrinology , antigen , biochemistry , medicine , environmental health
Summary Mice homozygous for the gld (generalized lymphoproliferative disease) mutation develop both lymphadenopathy and autoimmune disease. CD4 − CD8 − (double negative. DN) T cells comprise the major population of T cells in mature C3H‐ gld/gld peripheral lymphoid tissues. These DN T cells are unresponsive to many forms of stimuli and have previously been shown to exhibit abnormally elevated levels of membrane phosphotyrosine phosphalase (PTPase) activity. In the present study, we demonstrate that IP, production in response to mitogenic stimulation with Con A or anti‐CD3 mAb (145‐2C11) is significantly diminished in C3H‐ gld/gld lymphocytes when compared to that in congenic C3H‐ +/+ cells. The capacity to produce this second‐messenger can be restored by pretreating C3H‐ gld/gld cells with the PTPase inhibitor, phenylarsine oxide (PAO). Although the inhibition of PTPase activity by treatment with PAO did restore C3H‐ gld/gld cell ability to produce IP 3 the signal did not lead to lymphocyte proliferation, but instead to cell death. Our results suggest that the altered phosphoinositide hydrolysis observed in the mutant cells is related to their elevated membrane PTPase activity and that the anergy in these cells is at least in part related to the abnormally high activity of endogenous PTPases.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here